Summary of Cigna Group Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $71.7 billion.

Adjusted Earnings Per Share (EPS): $7.78, up from expectations.

Adjusted After-Tax Earnings: $2.1 billion.

Special Item Charges: $153 million or $0.58 per share.

Earnings Growth: Evernorth's Specialty and Care Services saw a 22% year-over-year growth in pretax adjusted earnings.

Cigna Healthcare: Revenues grew 10% year-over-year to $11.8 billion, with pretax adjusted earnings of $1.3 billion.

2Strategic Updates and Business Highlights

Evernorth Performance: Revenues increased 6% year-over-year, driven by strong demand for Specialty and Care Services.

Pharmacy Benefit Services: Transitioning to a new rebate-free model called Signature, with strong early interest from health plans and employers.

Innovations: Introduction of AI-driven programs like Pharmacy Forward to enhance patient care and streamline processes.

Focus on Personalization: Emphasis on delivering personalized health care experiences and actionable insights for clients and patients.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Increased to at least $30.45 for the full year 2026.

Earnings Seasonality: Expectation of second-half adjusted EPS to be evenly split between Q3 and Q4.

Evernorth Outlook: Anticipated pretax adjusted earnings of at least $6.9 billion for the full year.

Cigna Healthcare Outlook: Raising full-year pretax adjusted earnings to at least $4.55 billion.

4Bad News, Challenges, or Points of Concern

Pharmacy Benefit Services: Experienced a decline in pretax adjusted earnings due to the transition to the Signature model and moderating GLP-1 growth.

GLP-1 Drug Coverage: Cigna ended employee coverage for certain GLP-1 drugs, reflecting broader affordability challenges faced by clients.

IDR Mechanism: Concerns about the increasing volume of disputes favoring providers, which could exacerbate affordability issues for employers.

Market Volatility: Economic pressures and geopolitical uncertainties continue to pose risks to the business environment.

5Notable Q&A Insights

Earnings Growth in Evernorth: Analysts inquired about the growth trajectory in Specialty and Care Services, with management expressing confidence in continued strong performance despite some expected moderation in GLP-1 growth.

Selling Season Performance: Cigna reported strong new business wins for 2027, with retention rates above 97% and significant interest in the new Signature model.

Hospital Partnerships: Management highlighted opportunities for growth in the hospital and health system space, particularly through Shields Health Solutions.

Impact of ACA Exchange Exit: The exit from the ACA exchange business is expected to free up some capital, but there may be stranded overhead costs. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Cigna Group's performance and outlook for Q2 2026.